ARCHIVES

Genentech Move Nixes Hospital Discounts: Avastin, Herceptin, Rituxan Now Sold Under Tighter Control by Drug Maker

This article is from The Cancer Letter archive.

Vol. 40 No. 37 | October 3, 2014

Download PDF Visit The Full Archive

Related Articles

Ethics Commission Backs Limited Pilot Program for Compensation Of Injured Research Subjects

January 16, 1981

Gallo’s Lab Moved From DCT to DCE; NCI Planning To Drop “Cancer Treatment Reports” At End Of ‘86

February 6, 1987

ACOS Survey To Assess Tumor Boards’ Impact On Patient Care

January 24, 1986

Contract Awards Sole Source Negotiations

January 13, 1978

Cancer Advocacy: March On Washington Scheduled For September 1998

October 31, 1997

FDA developing guidelines for oncology endpoints.

May 7, 2004